In August, 2020, AstraZeneca exclusively grants BioKangtai a sublicense to develop, manufacture and commercialize the licensed products in the territory. The two sides will set up a joint steering committee. They will review, discuss and approve the overall strategy for the development of licensed products in the licensed area, including plans for R & D, production and commercialization of licensed products.
Under the agreement, BioKingtai will ensure annual production capacity of at least of 100 million doses of experimental shot AZD1222, which is co-developed by AstraZeneca and the University of Oxford.
